These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33091069)

  • 1. Correction: Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(10):e0241430. PubMed ID: 33091069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
    Lim KRQ; Yoon C; Yokota T
    J Pers Med; 2018 Nov; 8(4):. PubMed ID: 30477208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.
    Gee P; Xu H; Hotta A
    Stem Cells Int; 2017; 2017():8765154. PubMed ID: 28607562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.
    Zhu P; Wu F; Mosenson J; Zhang H; He TC; Wu WS
    Mol Ther Nucleic Acids; 2017 Jun; 7():31-41. PubMed ID: 28624206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome Editing Gene Therapy for Duchenne Muscular Dystrophy.
    Hotta A
    J Neuromuscul Dis; 2015 Sep; 2(4):343-355. PubMed ID: 27858753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.
    Himeda CL; Jones TI; Jones PL
    Trends Pharmacol Sci; 2016 Apr; 37(4):249-251. PubMed ID: 26917062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duchenne muscular dystrophy: CRISPR/Cas9 treatment.
    Mendell JR; Rodino-Klapac LR
    Cell Res; 2016 May; 26(5):513-4. PubMed ID: 26926391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
    Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
    PLoS One; 2020; 15(7):e0236916. PubMed ID: 32702009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.
    Bello L; Pegoraro E
    Acta Myol; 2016 Dec; 35(3):122-127. PubMed ID: 28484312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking progress: an update on animal models for Duchenne muscular dystrophy.
    Wells DJ
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29914884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.